NCT02873910

Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Others

Completed NA Last updated 3 January 2018

What this trial tests

NA trial testing IQP-AS-119 in Upper Respiratory Tract Symptoms in 75 participants. Completed in 31 October 2016.

Timeline

10 July 2016

Primary endpoint
31 October 2016

31 October 2016

Quick facts

Lead sponsor	InQpharm Group
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	75
Start date	10 July 2016
Primary completion	31 October 2016
Estimated completion	31 October 2016
Sites	1 location across Germany

Drugs / interventions tested

• IQP-AS-119
• Placebo

Conditions studied

• Upper Respiratory Tract Symptoms — all drugs for Upper Respiratory Tract Symptoms →

Sponsor

InQpharm Group

Who can join

Adults 18 to 65, any sex, with Upper Respiratory Tract Symptoms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the benefit and tolerability of IQP-AS-119 for reduction of susceptibility to infections and other complaints after extreme physical stress (participation in a marathon).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Investigation of the natural supplement IQP-AS-119 for the prevention of upper respiratory tract infections in marathon race participants: A randomized, double-blind, placebo-controlled pilot study.
   Bongartz U, Hochmann U, Pohl U, Bothe G, et al · · 2021 · PMID 33456511 · DOI 10.3892/etm.2020.9575